Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 ...

As an alternative, some doctors have been prescribing metformin—an oral diabetes drug—off-label for weight loss ... says ...

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced that the Company requested a post-complete letter clarification ...

Garner, MD, Medical Director at SimpleFixRx to review ... Medication produced by compounded pharmacies instead of the ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy ... binding pathway through the Cas13 RNA editor to knockdown VEGF-A mRNA.” Xin Zhang, MD, MSc, COO and CMO of HuidaGene, ...